menu search

Royalty pharma agrees to acquire royalty interest in olpasiran from arrowhead for $250 million and future milestones

olpasiran is an siRNA therapeutic being developed by Amgen to reduce risk of cardiovascular disease Arr...

November 9, 2022, 1:49 pm

Amgen (amgn) olpasiran lowers lipoprotein levels in phase ii

Amgen's (AMGN) olpasiran, a small interfering RNA molecule, is designed in such a way that it lowers th...

June 1, 2022, 10:32 am

Blue-chip stock could soon cool from recent rally

Blue-chip name Amgen, Inc.  (NASDAQ:AMGN) earlier reported its olpasiran therapy helped reduce chole...

May 31, 2022, 3:07 pm


Search within

Pages Search Results: